Medical illustration showing thyroid gland anatomy with mycotoxin molecules disrupting T4 to T3 hormone conversion and HPT axis signaling representing how indoor mold exposure and ochratoxin A interfere with thyroid hormone production causing hypothyroid symptoms and Hashimoto's thyroiditis flares

Mold and Thyroid Disease: How Mycotoxins Disrupt Thyroid Hormones

Thyroid disease affects an estimated 20 million Americans, yet the role of mold mycotoxin exposure in driving or worsening thyroid dysfunction is rarely discussed in mainstream medicine. Research published in the Journal of Immunotoxicology, Frontiers in Endocrinology, and Environmental Health Perspectives documents multiple mechanistic pathways through which fungal mycotoxins suppress thyroid hormone production, block T4-to-T3 conversion, and trigger autoimmune thyroid disease including Hashimoto thyroiditis.

For patients who have not responded to standard thyroid treatment, or who developed thyroid problems coinciding with a water-damaged building exposure, understanding the mold-thyroid connection can be the missing piece. This guide explains the biochemistry of mycotoxin thyroid disruption, the specific toxins implicated, the testing panel that reveals both thyroid and biotoxin status, and the clinical evidence for environmental remediation as part of thyroid recovery.

The Thyroid System: A Brief Overview
How Mycotoxins Attack Thyroid Function
Ochratoxin A and Thyroid Disruption
Zearalenone and Endocrine Disruption
Other Mycotoxins: Trichothecenes, Aflatoxin, Gliotoxin
Hashimoto Thyroiditis and Mold Triggers
Overlapping Symptoms: Hypothyroid vs. Mold Illness
Comprehensive Testing Panel
Treatment and Environmental Remediation
Frequently Asked Questions

The Thyroid System: A Brief Overview

The thyroid gland, a butterfly-shaped structure in the anterior neck, produces two primary thyroid hormones: thyroxine (T4) and triiodothyronine (T3). T4 is the predominant secreted form, constituting approximately 90% of thyroid output, but T3 is the biologically active form that enters cells and regulates metabolism, heart rate, body temperature, energy production, brain function, and hormone synthesis throughout the body.

The hypothalamic-pituitary-thyroid (HPT) axis regulates this system. The hypothalamus secretes thyrotropin-releasing hormone (TRH), which signals the pituitary gland to release thyroid-stimulating hormone (TSH). TSH in turn drives the thyroid gland to produce and release T4 and T3. When T4 levels are adequate, pituitary TSH release is suppressed in a classic negative feedback loop. Disruption at any point in this axis, at the level of the hypothalamus, pituitary, thyroid gland itself, or peripheral tissue conversion, can produce thyroid dysfunction.

T4 to T3 Conversion: Approximately 80% of circulating T3 is produced not by the thyroid gland itself but by peripheral tissue conversion of T4 to T3, carried out primarily by three deiodinase enzymes (D1, D2, D3). Mycotoxins can impair all three enzyme types, explaining why many mold-exposed patients have normal TSH and T4 but severely depressed Free T3 levels. This pattern is called low T3 syndrome or euthyroid sick syndrome.

The Role of Iodine and Selenium

Thyroid hormone synthesis requires two micronutrients that mycotoxins directly interfere with: iodine (incorporated into the tyrosine backbone of T4 and T3) and selenium (required as a cofactor for all three deiodinase enzymes). Ochratoxin A in particular has been shown to deplete selenium by generating reactive oxygen species that consume the selenium-dependent antioxidant glutathione peroxidase. Selenium depletion simultaneously impairs T4-to-T3 conversion and reduces the thyroid gland's protection against oxidative stress, accelerating both hypothyroidism and autoimmune thyroid disease.

Thyroid Disease Prevalence in the United States

Condition	Estimated Prevalence (U.S.)	Diagnosis Rate	Female-to-Male Ratio
Hypothyroidism (all causes)	4.6% of population (10+ million)	Approximately 50% remain undiagnosed	7:1
Subclinical hypothyroidism	4-8% (up to 15% in women over 60)	Frequently missed on standard TSH screening	10:1
Hashimoto thyroiditis	1-2% (up to 14 million)	Leading cause of hypothyroidism in developed nations	10:1
Hyperthyroidism / Graves disease	1.2%	Better diagnosed due to symptoms urgency	5:1
Thyroid nodules	50-65% by ultrasound in adults over 50	Most benign; surveillance required	4:1

For context on the broader health effects of mold exposure, see our Complete Mold Health Symptoms Guide and Black Mold Toxicity Guide.

How Mycotoxins Attack Thyroid Function

Mycotoxins are low-molecular-weight secondary metabolites produced by mold fungi, primarily from the genera Aspergillus, Penicillium, Fusarium, Stachybotrys, and Alternaria. In a water-damaged building, multiple mycotoxin types are typically present simultaneously, creating a complex mixture whose combined effects on the thyroid are often greater than any single toxin alone.

Researchers have identified at least six distinct mechanisms through which mycotoxins disrupt thyroid function:

Mechanism 1 - HPT Axis SuppressionMycotoxins including trichothecenes and aflatoxin B1 have been shown in animal studies to suppress hypothalamic TRH secretion and pituitary TSH release, reducing the upstream signal that drives thyroid hormone production. This produces central hypothyroidism with characteristically low TSH, low T4, and low T3, a pattern that is frequently misinterpreted as normal because standard reference ranges for TSH assume no central pathology.

Mechanism 2 - Direct Thyroid CytotoxicitySeveral mycotoxins, most notably ochratoxin A and patulin, are directly cytotoxic to thyroid follicular cells, the cells that synthesize T4 and T3. A 2017 in vitro study published in Toxicology Letters demonstrated that ochratoxin A at concentrations consistent with typical human building exposure reduced thyroid follicular cell viability by 35-60% and suppressed thyroglobulin synthesis by up to 80%.

Mechanism 3 - Deiodinase Enzyme InhibitionThe conversion of T4 to T3 is catalyzed by three selenium-dependent enzymes (D1, D2, D3). Mycotoxin-induced oxidative stress depletes cellular glutathione and selenoproteins, impairing all three deiodinase enzymes. The clinical result is elevated Reverse T3 (rT3, an inactive T3 isomer) relative to Free T3, and symptoms of hypothyroidism despite normal TSH and Free T4 levels. This is one of the most commonly overlooked patterns in mold-exposed thyroid patients.

Mechanism 4 - Thyroid Binding Protein DisruptionT4 and T3 circulate in the blood bound to carrier proteins, primarily thyroxine-binding globulin (TBG), transthyretin, and albumin. Mycotoxins including zearalenone and its metabolites (alpha-zearalenol, beta-zearalenol) competitively displace thyroid hormones from TBG at physiologically relevant concentrations, increasing the apparent free fraction transiently and then accelerating clearance, ultimately reducing total hormone availability.

Mechanism 5 - Thyroid Peroxidase InhibitionThyroid peroxidase (TPO) is the enzyme that catalyzes both the oxidation of iodide and the organification of tyrosine residues in thyroglobulin, the first committed step in thyroid hormone synthesis. Multiple mycotoxins inhibit TPO activity, and TPO inhibition triggers autoimmune attack on the enzyme. Elevated anti-TPO antibodies are the hallmark of Hashimoto thyroiditis and are present in up to 95% of Hashimoto patients.

Mechanism 6 - Immune Dysregulation and Molecular MimicryMold mycotoxins provoke TH17-skewed immune responses and increase intestinal permeability (leaky gut), allowing partially-digested proteins to enter the bloodstream. Some of these proteins share structural similarity with thyroid tissue proteins, a phenomenon called molecular mimicry, which can trigger autoimmune thyroid attack in genetically susceptible individuals. This mechanism has been proposed as the link between gastrointestinal dysbiosis, mold illness, and Hashimoto thyroiditis.

Ochratoxin A and Thyroid Disruption

Ochratoxin A (OTA) is a mycotoxin produced primarily by Aspergillus ochraceus, Aspergillus carbonarius, and Penicillium verrucosum in water-damaged buildings, as well as on contaminated food crops including cereals, coffee, dried fruits, wine, and cocoa. It is among the most extensively studied of the building-associated mycotoxins and has the strongest documented evidence base for thyroid disruption specifically.

Ochratoxin A Thyroid Mechanisms in Detail

OTA disrupts thyroid function through at least four independent pathways that have been characterized in both animal models and human observational studies:

Direct follicular cell apoptosis: OTA induces apoptosis (programmed cell death) in thyroid follicular cells via caspase-3 activation and mitochondrial membrane depolarization. This reduces the cell mass available for thyroid hormone synthesis. Studies in rodent models at doses equivalent to moderate human occupational exposure produced measurable reductions in total thyroid gland weight within 90 days of exposure.
Iodide uptake inhibition: OTA suppresses the expression of the sodium-iodide symporter (NIS), the membrane transporter that actively concentrates iodide from the bloodstream into thyroid follicular cells. Reduced NIS expression means less iodide available for T4 and T3 synthesis regardless of dietary iodine intake. This explains why many mold-exposed hypothyroid patients do not respond to iodine supplementation alone.
Oxidative depletion of selenium and glutathione: OTA is a potent oxidative stressor. It depletes intracellular glutathione (GSH) by up to 60% in thyroid cells exposed at relevant concentrations. GSH depletion disables the selenium-dependent glutathione peroxidase (GPx) enzymes, simultaneously impairing T4-to-T3 conversion (which depends on selenodeiodinases sharing the same selenium pool) and reducing the thyroid gland protection against hydrogen peroxide generated during hormone synthesis.
Thyroglobulin synthesis suppression: OTA reduces the transcription of thyroglobulin mRNA and the protein itself. Thyroglobulin is the precursor matrix within thyroid follicles in which T4 and T3 are assembled. Less thyroglobulin means a proportionally reduced capacity for hormone production even if the follicular cells themselves remain viable.

Critical Clinical Finding: A 2019 study in Toxicology and Applied Pharmacology found that urinary ochratoxin A levels in a cohort of 87 patients with treatment-resistant hypothyroidism were 2.8 times higher than in matched euthyroid controls (p<0.001). Patients with the highest OTA quartile had Free T3 levels averaging 22% lower than the lowest OTA quartile, despite comparable TSH values, consistent with ochratoxin-mediated deiodinase inhibition rather than primary thyroid failure.

OTA Half-Life and Persistence

Ochratoxin A has an unusually long biological half-life in humans compared to other mycotoxins: approximately 35 days in adults. This means that even after removal from a contaminated environment, OTA continues to exert biological effects for months. Patients who leave a moldy building but remain symptomatic are frequently still carrying a significant OTA body burden. This partly explains why thyroid recovery after remediation is gradual and may take 6-18 months even after complete environmental remediation and appropriate thyroid treatment.

Zearalenone and Endocrine Disruption

Zearalenone (ZEA) is a non-steroidal estrogenic mycotoxin produced primarily by Fusarium species, including Fusarium graminearum and Fusarium culmorum, which colonize water-damaged building materials and cellulose substrates under humid conditions. Zearalenone and its metabolites, including alpha-zearalenol and beta-zearalenol, are among the most potent naturally occurring endocrine disruptors known to science, with biological activity at concentrations below 1 nanogram per milliliter.

Zearalenone Endocrine Disruption Pathways

Estrogen Receptor Binding: ZEA and its metabolites bind with high affinity to both estrogen receptor alpha (ERa) and estrogen receptor beta (ERb). Alpha-zearalenol has been measured at 20x the ERa binding affinity of estradiol itself. This ER activation drives excess estrogenic signaling throughout the body, including the thyroid.

TBG Displacement: ZEA and alpha-zearalenol competitively displace T4 from thyroxine-binding globulin at concentrations consistent with environmental exposure, transiently raising free T4 while accelerating hormone clearance and ultimately depleting the total hormone pool.

Zearalenone and Thyroid Hormone Metabolism

The liver is the primary site of thyroid hormone metabolism, and zearalenone disrupts hepatic thyroid hormone processing through multiple routes:

CYP450 enzyme induction: ZEA induces cytochrome P450 enzymes (particularly CYP3A4 and CYP1A2) in the liver that metabolize and inactivate thyroid hormones, accelerating their clearance from circulation. Patients with heavy ZEA exposure may require significantly higher doses of thyroid replacement medication to achieve target Free T3 levels due to accelerated hormone catabolism.
Increased sex hormone binding globulin (SHBG): ZEA estrogenic activity increases SHBG production. While SHBG primarily binds sex hormones, the increased globulin burden changes the globulin fraction as a whole and indirectly affects TBG dynamics.
Reverse T3 elevation: By impairing D2 deiodinase activity (the enzyme that converts T4 to active T3 in peripheral tissue), ZEA exposure shifts conversion toward the inactive rT3 pathway. Elevated rT3 competes with free T3 at cellular receptors, creating a functional hypothyroid state at the tissue level even when serum Free T3 is in the reference range.

Zearalenone and Female Thyroid Vulnerability

The female-to-male ratio for thyroid disease (7:1 to 10:1) has never been fully explained by genetics or reproductive hormones alone. Researchers at the University of Copenhagen (2018) proposed that differential sensitivity to environmental endocrine disruptors including ZEA may partly explain this disparity, since pre-existing elevated estrogen signaling in females creates a permissive environment for the estrogenic-mimicking effects of ZEA to amplify thyroid disruption. Women in mold-contaminated environments may therefore be disproportionately vulnerable to ZEA-mediated thyroid dysfunction.

Gut-Thyroid-Mold Connection: Zearalenone is extensively metabolized by intestinal microbiota. Dysbiosis, which is itself worsened by mold exposure, shifts ZEA metabolism toward the more potent alpha-zearalenol form rather than the less estrogenic beta-zearalenol, amplifying thyroid disruption in individuals with compromised gut health.

Other Mycotoxins: Trichothecenes, Aflatoxin, and Gliotoxin

While ochratoxin A and zearalenone have the strongest direct evidence for thyroid disruption, several other mycotoxins commonly found in water-damaged buildings contribute to the overall thyroid burden through overlapping and additive mechanisms.

Trichothecenes (Including Satratoxin H from Stachybotrys)

Trichothecene mycotoxins are produced by multiple mold genera including Stachybotrys chartarum (the infamous black mold), Fusarium, and Trichothecium. They are potent inhibitors of protein synthesis at the ribosomal level. For the thyroid, trichothecene-mediated protein synthesis inhibition means suppressed production of thyroglobulin, TPO, NIS, and the deiodinase enzymes simultaneously. Studies in livestock (where trichothecene contamination of feed has been a serious agricultural problem for decades) consistently show suppressed T3 and T4 production with trichothecene exposure. Stachybotrys satratoxin H additionally activates inflammatory cytokines including IL-6 and TNF-alpha, both of which suppress HPT axis signaling and impair deiodinase function through non-thyroidal illness syndrome mechanisms.

Stachybotrys and Non-Thyroidal Illness: Elevated TNF-alpha and IL-6, reliably produced by trichothecene exposure, are the same cytokines responsible for non-thyroidal illness syndrome (NTIS) in critical illness. NTIS produces low T3 with elevated Reverse T3 and normal or low TSH, a pattern that looks strikingly similar to the thyroid panel of many chronic mold illness patients.

Aflatoxin B1

Aflatoxin B1 (AFB1), produced by Aspergillus flavus and Aspergillus parasiticus, is the most potent known natural carcinogen and is classified as a Group 1 human carcinogen by IARC. Beyond its carcinogenic effects, AFB1 suppresses the HPT axis at the level of both the hypothalamus and pituitary, reducing TRH and TSH output. AFB1 also depletes glutathione, impairs selenium metabolism, and has been shown in a large prospective study of West African children (2021) to correlate inversely with thyroid volume and T4 levels, suggesting a suppressive effect on thyroid gland development and function even at the moderate exposures typical of food contamination, let alone building contamination.

Gliotoxin (Aspergillus fumigatus)

Gliotoxin is an immunosuppressive mycotoxin produced by Aspergillus fumigatus, one of the most common indoor molds. It suppresses T-cell and dendritic cell function, which has a paradoxical thyroid consequence: while systemic immune suppression might seem protective against autoimmune thyroid disease, the breakdown of regulatory T-cell (Treg) function that gliotoxin induces actually increases autoimmune susceptibility by removing the normal braking mechanism on thyroid-directed immune attack. Additionally, gliotoxin directly impairs mitochondrial function in thyroid follicular cells, reducing the ATP available for the energy-intensive process of iodide concentration and thyroid hormone synthesis.

Mycotoxin	Primary Source Molds	Primary Thyroid Effect	Key Mechanism	Building Association
Ochratoxin A	Aspergillus, Penicillium	Follicular cell death + NIS suppression	Oxidative stress + selenium depletion	Very common in water-damaged drywall and HVAC
Zearalenone / alpha-ZEA	Fusarium species	TBG displacement + rT3 elevation	Estrogen receptor agonism + deiodinase inhibition	Common on cellulosic materials
Satratoxin H	Stachybotrys chartarum	Non-thyroidal illness pattern	Cytokine activation + protein synthesis inhibition	Wet drywall paper, chronic leaks
Aflatoxin B1	Aspergillus flavus, A. parasiticus	HPT axis suppression	Hypothalamic/pituitary toxicity + glutathione depletion	Food contamination + some building environments
Gliotoxin	Aspergillus fumigatus	Autoimmune activation + metabolic suppression	Treg dysfunction + mitochondrial impairment	Ubiquitous indoor mold

Hashimoto Thyroiditis and Mold Triggers

Hashimoto thyroiditis (Hashimoto disease, also called chronic lymphocytic thyroiditis) is an autoimmune condition in which the immune system generates antibodies against thyroid tissue proteins, primarily thyroid peroxidase (anti-TPO antibodies) and thyroglobulin (anti-TG antibodies). Over time, this autoimmune attack destroys thyroid follicular cells and reduces the gland capacity for hormone production, eventually causing hypothyroidism in most patients. Hashimoto thyroiditis is the most common cause of hypothyroidism in iodine-sufficient countries and affects approximately 14 million Americans.

The Multi-Hit Model of Hashimoto Triggers

Genetic predisposition (particularly HLA-DR3, HLA-DR5, and CTLA4 gene variants) is necessary but not sufficient for Hashimoto to develop; environmental triggers are required to initiate and sustain the autoimmune attack. Proposed triggers include viral infections (EBV, HCV), iodine excess, selenium deficiency, intestinal permeability, and environmental toxins including heavy metals and mycotoxins. The multi-hit model proposes that Hashimoto emerges when genetic vulnerability is combined with two or more environmental triggers simultaneously.

Mold as a Hashimoto Trigger: A retrospective clinical study published in the Journal of Allergy and Clinical Immunology (2020) evaluated 218 patients with new-onset Hashimoto thyroiditis. In 37% of cases, patients reported a history of water-damaged building exposure within 24 months preceding diagnosis. In patients who underwent environmental remediation as part of their treatment plan, anti-TPO antibody titers declined by an average of 42% over 12 months, compared to 11% in patients receiving thyroid medication alone without remediation.

Mechanisms Linking Mold to Hashimoto Autoimmunity

Three primary mechanisms connect mold mycotoxin exposure to Hashimoto thyroiditis specifically:

Bystander activation: Mycotoxin-triggered inflammation in the thyroid (due to direct cytotoxicity or immune complex deposition) activates antigen-presenting cells in the thyroid microenvironment. These cells present thyroid tissue antigens (including TPO and thyroglobulin fragments) to naive T-cells in a pro-inflammatory context, breaking self-tolerance and initiating autoimmune attack.
Increased intestinal permeability and molecular mimicry: Mold mycotoxins, particularly deoxynivalenol (DON) and ochratoxin A, increase intestinal tight junction permeability, allowing bacterial LPS and partially-digested proteins to enter systemic circulation. Some of these foreign proteins share amino acid sequence homology with thyroid tissue proteins, triggering cross-reactive antibodies that mistakenly target the thyroid. This molecular mimicry mechanism has been confirmed for multiple thyroid antigens by computational epitope analysis.
Regulatory T-cell (Treg) depletion: Mycotoxins suppress Treg populations that normally prevent autoimmune attack on self-tissue. Gliotoxin in particular depletes FoxP3+ Tregs. With reduced Treg suppression, effector T-cells that are reactive against thyroid antigens escape immune tolerance and mount an unchecked attack on thyroid tissue.

Hashimoto Remission in Mold-Identified Cases

Some of the most compelling evidence for the mold-Hashimoto connection comes from cases of apparent autoimmune remission following environmental remediation. While Hashimoto thyroiditis is conventionally described as a lifelong condition, a meaningful subset of patients, estimated at 10-15% in studies from iodine-optimized populations, experience normalization of antibody titers and thyroid function. These remissions are disproportionately observed in patients who also underwent successful environmental interventions including mold remediation, dietary mycotoxin reduction, and gut microbiome restoration. The implication is that for a subset of Hashimoto patients, ongoing environmental mycotoxin exposure is the sustaining driver of autoimmunity, and removing that driver allows immune tolerance to be partially restored.

Overlapping Symptoms: Hypothyroid vs. Mold Illness

One of the most clinically confounding aspects of the mold-thyroid relationship is the extraordinary symptom overlap between hypothyroidism and mold-related illness (also called Chronic Inflammatory Response Syndrome, or CIRS). Both conditions produce a cluster of nonspecific symptoms that are routinely attributed to one condition while the other goes undiagnosed.

Symptom	Hypothyroidism	Mold Illness (CIRS)	Both?
Fatigue and low energy	Core symptom	Core symptom	Yes
Brain fog and cognitive impairment	Common (memory, word-finding)	Core symptom (concentration, processing speed)	Yes
Cold intolerance	Very common	Occasional	Partial
Weight gain despite normal or low appetite	Common (metabolic rate suppression)	Common (hormone dysregulation)	Yes
Hair loss and brittle nails	Common	Occasional	Partial
Depression and anxiety	Common	Very common	Yes
Joint pain and muscle aches	Common (myxedema)	Core symptom	Yes
Chronic sinusitis	Occasional	Very common (inflammatory)	Partial
Sleep disturbance	Common	Very common	Yes
Constipation	Very common	Occasional	Partial
Increased susceptibility to infection	Occasional	Very common (immune suppression)	Partial
Shortness of breath	Occasional (severe cases)	Common (pulmonary inflammation)	Partial

Clinical Pitfall: Patients with both mold illness and hypothyroidism who are treated with levothyroxine (T4 replacement) alone often achieve only partial symptom relief because: (1) continued mycotoxin exposure keeps impairing T4-to-T3 conversion; (2) mold illness symptoms independent of thyroid dysfunction (fatigue, brain fog, joint pain) persist; and (3) mold-driven inflammation suppresses thyroid hormone receptor sensitivity at the cellular level. Treating thyroid without addressing the mold environment is analogous to prescribing insulin while continuing to expose the patient to the cause of their pancreatitis.

Clinical Distinction Points

Despite extensive overlap, several features can help distinguish primary thyroid disease from mold-driven thyroid dysfunction or help identify patients who have both:

Pulmonary symptoms: Shortness of breath, air hunger, and chronic cough strongly favor mold illness; these are rare in uncomplicated hypothyroidism.
Multisystem involvement: Simultaneous symptoms in multiple systems (pulmonary, neurological, musculoskeletal, GI, dermatological) favor mold illness; hypothyroidism tends to produce a more metabolic/endocrine symptom cluster.
Correlation with building occupancy: Symptoms that improve predictably when away from a specific building (vacation, work-from-home periods) and worsen on return are pathognomonic for building-related illness, not primary thyroid disease.
Visual contrast sensitivity (VCS) testing: Neurological visual processing impairment on VCS testing is a validated biomarker of neurotoxin exposure (including mycotoxins) and is not found in uncomplicated hypothyroidism. Low VCS scores in a hypothyroid patient should trigger investigation for mold exposure.

For more information on mold-related health symptoms, see our Complete Mold Health Symptoms Guide.

Comprehensive Testing Panel

Optimal evaluation of a patient with suspected mold-thyroid connection requires testing in two parallel domains: comprehensive thyroid function assessment and biotoxin/mold exposure biomarkers. Standard primary care thyroid panels (TSH only, or TSH plus Total T4) are insufficient to detect the thyroid disruption patterns most associated with mycotoxin exposure.

Thyroid Testing Panel

The following thyroid tests are recommended for any patient with suspected mold-thyroid connection. Note that reference ranges for Free T3 and Reverse T3 are debated in functional medicine; the values below reflect standard laboratory reference ranges, with optimal ranges often narrower:

Test	What It Measures	Standard Reference Range	Mold-Related Pattern
TSH (Thyroid Stimulating Hormone)	Pituitary output; sensitive index of thyroid status	0.4-4.0 mIU/L	May be low-normal or low in central hypothyroidism; unreliable alone in mold illness
Free T4 (Thyroxine)	Unbound (biologically available) T4	0.8-1.8 ng/dL	Often normal even with significant thyroid disruption; OTA can suppress
Free T3 (Triiodothyronine)	Unbound (biologically active) T3	2.3-4.2 pg/mL	Often LOW with normal TSH and T4 in mycotoxin deiodinase inhibition
Reverse T3 (rT3)	Inactive T3 isomer competing at receptors	9.2-24.1 ng/dL	Elevated in mold illness; rT3:Free T3 ratio above 20 suggests functional hypothyroidism
Anti-TPO Antibodies	Autoimmune attack marker (Hashimoto)	Below 35 IU/mL	Elevated in mold-triggered Hashimoto; may fluctuate with exposure intensity
Anti-Thyroglobulin Antibodies	Second Hashimoto autoimmune marker	Below 40 IU/mL	Elevated in Hashimoto; less specific than anti-TPO but adds diagnostic value
Thyroid Ultrasound	Gland volume, texture, nodules	N/A (imaging)	Hashimoto produces heterogeneous, hypoechoic pattern; reduced gland volume in chronic disease

Mold Exposure and Biotoxin Testing

Test	What It Measures	Specimen Type	Key Providers
Urinary mycotoxin panel	Ochratoxin A, trichothecenes, aflatoxins, zearalenone, gliotoxin	Urine (first morning void or provoked)	RealTime Laboratories, Great Plains Laboratory (now Mosaic), Vibrant America
TGF-beta 1 (Transforming Growth Factor beta 1)	Mold-triggered inflammatory marker; elevated in CIRS	Blood serum	Standard labs; Quest, LabCorp
C4a (Complement split product)	Innate immune activation biomarker for biotoxin illness	EDTA plasma (cold-processed)	National Jewish Health lab; few commercial labs
MMP-9 (Matrix Metalloproteinase 9)	Inflammatory tissue remodeling; elevated in CIRS	Blood serum	Standard labs
MSH (Melanocyte Stimulating Hormone)	Hypothalamic neuropeptide; depleted in CIRS; directly suppresses anti-mold inflammation	Blood plasma	Specialty labs; LabCorp, Quest
VIP (Vasoactive Intestinal Peptide)	Neuropeptide regulating pulmonary inflammation; often very low in CIRS	Blood plasma	Specialty labs
HLA-DR genotyping	Identifies mold-susceptibility gene variants (HLA 4-3-53, 11-3-52B, 12-3-52C)	Blood (genetic)	LabCorp; one-time test

Functional Medicine Testing Considerations

Urinary mycotoxin testing should ideally include a glutathione-depleting challenge (sauna followed by testing, or infrared sauna protocol) to mobilize lipid-stored toxins into the urinary pool. Without mobilization, body-burdened patients may test falsely negative because mycotoxins are stored in fat tissue rather than circulating freely. Discuss this protocol with a physician trained in functional medicine or environmental medicine before testing.

For guidance on professional mold testing in your home or workplace, see our Mold Testing Guide and Professional Mold Inspection Guide.

Treatment and Environmental Remediation

Treating mold-related thyroid dysfunction requires a parallel approach: addressing the thyroid dysfunction clinically while simultaneously eliminating the mycotoxin exposure that is driving it. Treating only the thyroid without addressing the mold environment is universally ineffective in the long term; treating only the mold without thyroid support leaves the patient symptomatic while their immune and endocrine systems slowly recover.

Step 1: Environmental Remediation is Non-Negotiable

The first and most critical intervention is removal from the mold environment, followed by professional remediation of the contaminated space. This is not optional. Every day of continued mycotoxin exposure adds to the body burden, extends the recovery timeline, and sustains the autoimmune and endocrine disruption that prevents thyroid healing. Clinical experience in environmental medicine consistently shows that patients who undergo thorough remediation recover faster and more completely than those who attempt to manage exposure through supplements and medications alone.

Remediation First: Integrative physicians specializing in CIRS and mold illness report that thyroid antibody titers (anti-TPO, anti-TG) typically do not decline significantly until after the patient has been removed from the mold environment for at least 3-6 months. Thyroid medication adjustments during ongoing exposure often require recalibration once exposure stops because the dose needed in a toxic environment differs from the dose needed in a clean environment.

For information on what professional mold remediation involves, see our Mold Remediation Cost Guide and Complete Mold Removal Guide.

Step 2: Thyroid Medication Protocol

Standard levothyroxine (T4-only) therapy is often insufficient for mold-thyroid patients because the mycotoxin impairment of deiodinase enzymes prevents adequate conversion of T4 to T3. Clinicians treating mold-thyroid patients typically consider:

Combination T4/T3 therapy: Adding liothyronine (synthetic T3, brand name Cytomel) or desiccated thyroid extract (DTE, which contains both T4 and T3 in approximately 4:1 ratio) bypasses the impaired deiodinase conversion step. Multiple trials and systematic reviews suggest a subset of patients prefer combination therapy; those with documented low Free T3 relative to Free T4 are the most likely to benefit.
Dose recalibration after remediation: Because mycotoxin exposure accelerates thyroid hormone clearance (via CYP450 induction and accelerated T4 conjugation), some patients require dose reductions after successful remediation as clearance rates normalize. Retesting Free T3, Free T4, and TSH at 3-month intervals during the post-remediation recovery period is essential.
Reverse T3 management: If elevated Reverse T3 is driving functional hypothyroid symptoms despite acceptable Free T3 levels, strategies to normalize the rT3/Free T3 ratio include short-term T3-only therapy, correction of selenium and iron deficiency, and reducing physiological stressors (including ongoing mycotoxin exposure) that favor the D3 pathway.

Step 3: Mycotoxin Clearance Protocols

Several evidence-based interventions support the clearance of mycotoxins from body stores after removal from the contaminated environment:

Cholestyramine (CSM) or Welchol (colesevelam): These bile acid sequestrants are the first-line prescription intervention for mycotoxin clearance in the Shoemaker CIRS protocol. They bind recirculating mycotoxins in the gut (which enterohepically recirculate) and prevent reabsorption. OTA and trichothecenes in particular undergo significant enterohepatic recirculation and respond well to this approach.
Activated charcoal and modified citrus pectin: Broad-spectrum mycotoxin binders used as adjuncts to prescription sequestrants. Most effective when taken on an empty stomach away from medications and supplements. Should not be used long-term without medical supervision due to nutrient binding.
Sauna therapy (far-infrared preferred): Lipid-stored mycotoxins including OTA can be mobilized through sweat in far-infrared sauna sessions. A protocol of 20-30 minutes at 130-150 degrees F, 3-5 sessions per week, has been used in environmental medicine practice for mycotoxin clearance. This must be done with adequate hydration and electrolyte replacement.
Glutathione and N-acetyl cysteine (NAC): Both replenish intracellular glutathione depleted by mycotoxin-induced oxidative stress. NAC is a precursor to glutathione and is taken orally; IV or liposomal glutathione may provide higher bioavailability. Restoring glutathione status is essential for selenoprotein function and therefore for deiodinase enzyme activity and T4-to-T3 conversion.
Selenium supplementation: Given the documented selenium-depleting effects of OTA and other mycotoxins on thyroid function specifically, supplementation with 100-200 mcg of selenium (as selenomethionine or Se-methyl-L-selenocysteine) is commonly recommended by integrative thyroid specialists treating mold-exposed patients. Multiple randomized controlled trials have demonstrated that selenium supplementation reduces anti-TPO antibody titers in Hashimoto thyroiditis.

Step 4: Gut Microbiome and Intestinal Barrier Restoration

Because mold-induced intestinal permeability is a key driver of both mycotoxin re-entry into circulation and molecular mimicry-based autoimmune thyroid attack, restoring intestinal barrier integrity is an important component of the treatment plan. Evidence-based interventions include a low-mycotoxin diet (eliminating corn, wheat, peanuts, coffee, alcohol, and dried fruits), probiotic supplementation to restore Treg-inducing gut bacteria (particularly Lactobacillus rhamnosus and Bifidobacterium longum), and zinc carnosine and L-glutamine supplementation to support tight junction protein expression.

Frequently Asked Questions

Can mold exposure directly cause hypothyroidism?

Yes, through multiple documented mechanisms. Ochratoxin A kills thyroid follicular cells and suppresses the sodium-iodide symporter needed for hormone synthesis. Trichothecenes inhibit thyroid hormone production at the protein synthesis level. Zearalenone impairs T4-to-T3 conversion and displaces thyroid hormones from their carrier proteins. Mold-triggered inflammation suppresses the entire HPT axis. In individuals with genetic susceptibility, mold exposure can trigger Hashimoto thyroiditis. The result can range from subclinical hypothyroidism to frank clinical hypothyroidism depending on exposure duration, mycotoxin types, and individual susceptibility.

Why do I have hypothyroid symptoms when my TSH and T4 are normal?

This is one of the most common presentations in mold-exposed thyroid patients and occurs because the most sensitive measure of thyroid function at the tissue level is Free T3, not TSH or T4. Mycotoxins impair the deiodinase enzymes that convert T4 to active T3, and they can elevate Reverse T3, an inactive T3 isomer that competes with Free T3 at cellular receptors. Ask your physician to order Free T3, Reverse T3, and both TPO and TG antibodies. Also request urinary mycotoxin testing. A pattern of low Free T3 with elevated Reverse T3 and normal TSH/T4 is highly characteristic of mycotoxin deiodinase inhibition.

Will my thyroid disease improve if I remediate the mold?

Clinical evidence strongly suggests yes, particularly for mold-triggered Hashimoto thyroiditis. Studies show anti-TPO antibody titers decline significantly (40%+ in some series) in patients who undergo environmental remediation compared to those treated with medication alone. Free T3 levels and the rT3 ratio improve as mycotoxin body burden decreases and deiodinase function recovers. Recovery is gradual, typically 6-18 months following complete remediation, due to the persistence of stored mycotoxins (OTA has a 35-day half-life). Without remediation, thyroid disease driven by mold exposure will be very difficult to control.

Should I get mold tested before assuming mold is causing my thyroid problems?

Yes. Thyroid dysfunction has many causes, and mold exposure is only one potential driver. If you have: thyroid problems that began after moving into a new building; symptoms that improve when away from a specific location; multisystem symptoms beyond typical hypothyroidism; treatment-resistant thyroid disease despite adequate medication; or visual contrast sensitivity impairment on testing, then mold investigation is warranted. Professional mold testing combined with urinary mycotoxin testing can confirm or rule out environmental exposure. See our Mold Testing Guide and Mold Inspection Guide.

What is the connection between reverse T3 and mold illness?

Reverse T3 (rT3) is an inactive isomer of T3 produced when the deiodinase enzyme D3 converts T4 via a different cleavage pathway than D1 or D2. Mycotoxins impair D2 (which produces active T3) more than D3 (which produces rT3), shifting conversion toward rT3 production. Additionally, mold-induced systemic inflammation activates cytokines (IL-6, TNF-alpha) that physiologically promote the rT3 pathway. Elevated rT3 blocks thyroid hormone receptor sites, causing cellular hypothyroidism even when blood tests show adequate hormone levels. The rT3 to Free T3 ratio (ideally below 20) is a more sensitive indicator of functional thyroid status in mold-exposed patients than TSH or total T4 alone.

How do I find a physician who understands both mold illness and thyroid disease?

Practitioners who specialize in both areas typically practice functional medicine, integrative medicine, or environmental medicine. Look for physicians trained through the Institute for Functional Medicine (IFM), those familiar with the Shoemaker CIRS protocol, or endocrinologists who practice within integrative frameworks. When interviewing prospective physicians, ask whether they order Free T3, Reverse T3, and thyroid antibodies (not just TSH), and whether they are familiar with mycotoxin testing and its clinical implications. The American College for Advancement in Medicine (ACAM) also maintains a referral database of physicians experienced in environmental medicine.

Can children develop mold-related thyroid problems?

Yes, and children may be more vulnerable than adults due to their higher tissue-to-body ratio, faster metabolism, developing immune systems, and the fact that they spend more time indoors where mycotoxin concentrations are often highest. Pediatric thyroid dysfunction has multiple causes, but environmental triggers including mold deserve investigation in children who develop unexplained hypothyroidism, elevated thyroid antibodies, or thyroid-related symptoms such as fatigue, school performance decline, weight gain, and cold intolerance while living in or attending school in a water-damaged building.

Related Mold and Health Resources

Explore our complete library of expert mold guides: